



Perma-Fix Medical Provides Business Update

Schedules Investor Webcast for May 26th at 4:00 PM Central European Time

Warsaw and Atlanta – May 26, 2015 – Perma-Fix Medical S.A. (WAR: PFM), a subsidiary of Perma-Fix Environmental Services, Inc., a NASDAQ listed company, today provided a general business update. The Company also announced it will host a business update call at 4:00 PM Central European time (10:00 a.m. Eastern time) on Tuesday, May 26, 2015, via webcast on the company's website: www.medical-isotope.com.

Dr. Louis F. Centofanti, Chief Executive Officer of Perma-Fix Medical S.A. stated, "We continue to advance the Technetium-99m (Tc-99m) production process towards commercialization in Europe and the U.S. Our technology has previously been validated at two leading nuclear institutions. We are presently scaling up the process at higher curie levels and will disclose more on this front in the very near future. As a next step, we are also focused on establishing strategic partnerships with additional companies involved in the Tc-99m supply chain. We believe our innovative process of Tc-99m production will be extremely well received in both North America and Europe as it addresses the global need for a safer, more reliable, more cost-effective and uranium-free solution to Tech-99m production."

"At the upcoming shareholder meeting of Perma-Fix Medical S.A., on June 2, 2015, we also look forward to announcing new senior management executives, pending shareholder approval. We believe that we have assembled an impressive team of leading experts with proven track records in their respective areas of expertise to help accelerate our activities going forward. The shareholders are also expected to approve the issuance of new shares to Digirad Corporation in order to close their \$1 million strategic investment in Perma-Fix Medical. We are pleased to have developed a strong relationship with Digirad, one of the largest U.S. providers of in-office nuclear cardiology imaging services. We anticipate Digirad will be one of the main buyers of Tc-99m supplied by Perma-Fix Medical."

Dr. Centofanti continued, "As Perma-Fix Medical is still in the development stage, we did not generate revenue in the first quarter of 2015 but we have carefully managed our research and development expenses. We believe the funding obtained and the additional funding that is expected to come from our recent private placement, along with the grant funding and the investment by Digirad Corporation, provide us with the necessary capital to complete the next steps."

The conference call can be accessed via a live Internet webcast on the Company's website at www.medical-isotope.com. A webcast replay of the conference call will be accessible on the Company's website at www.medical-isotope.com for 90 days.

About Perma-Fix Medical

Perma-Fix Medical is a subsidiary of Perma-Fix Environmental Services Inc., a NASDAQ listed company. It was formed to develop, obtain FDA and other regulatory approval and commercialize a new process to produce Technetium-99 (Tc-99m), the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors.

Please visit us on the World Wide Web at <http://www.medical-isotope.com>.

Contacts:

Justyna Gudaszwaska or David K. Waldman
Crescendo Communications Europe Sp. z.o.o
Tel: (+48 71) 79 11 551
Email : pfm@crescendo-ir.com